Clinical Scorecard: Aegeline Reduces Myocardial Infarction Induced by Isoproterenol: Findings from Biochemical, Histopathological, and In Silico Analyses
At a Glance
Category
Detail
Condition
Myocardial Infarction
Key Mechanisms
Antioxidant and anti-inflammatory properties of aegeline reduce oxidative stress and inflammation.
Target Population
Experimental models of myocardial infarction in rats.
Care Setting
Experimental research setting.
Key Highlights
Aegeline demonstrated cardioprotective effects against isoproterenol-induced myocardial injury.
Histopathological analysis showed reduced myocardial damage with aegeline treatment.
Aegeline improved antioxidant and oxidative stress markers.
Molecular docking revealed strong binding affinity of aegeline for CK-MB.
Aegeline did not adversely affect liver or kidney function.
Guideline-Based Recommendations
Diagnosis
Use of isoproterenol to induce myocardial infarction in experimental models.
Management
Administration of aegeline at doses of 5 and 10 mg in experimental settings.
Monitoring & Follow-up
Assessment of biochemical markers and histopathological features post-treatment.
Risks
Potential for oxidative stress and inflammation in myocardial injury.
Patient & Prescribing Data
Not applicable; study conducted in experimental rat models.
Aegeline shows promise as a cardioprotective agent in myocardial infarction.
Clinical Best Practices
Consider natural products like aegeline for their potential cardioprotective effects.
Monitor oxidative stress and inflammatory markers in myocardial injury models.
by Sami I. Alzarea, Muhammad Afzal, Misbahuddin Rafeeq, Alaa Hamed Habib, Tariq G. Alsahli, Omar Awad Alsaidan, Hassan H. Alhassan, Abdulaziz Ibrahim Alzarea, Aseel Awad Alsaidan, Nadeem Sayyed, Imran Kazmi
